Provention Bio, Inc. – NASDAQ:PRVB

Add to watchlist

Market closed

Open in about 15 hours

+4.56%

month

+186.80%

quarter

+396.62%

year

Market Cap	2.37B
Enterprise value	1.79B

P/E	-15.86
EV/Sales	126.05
EV/EBITDA	-11.42
Price/Sales	127.47
Price/Book	14.87
PEG ratio	-0.98
EPS	-1.6

Revenue	12.89M
EBITDA	-124.89M
Income	-112.97M
Revenue Q/Q	1408.08%
Revenue Y/Y	824.37%

Profit margin	-1161.8%
Oper. margin	-1315.48%
Gross margin	87.01%
EBIT margin	-1315.48%
EBITDA margin	-968.55%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Provention Bio, Inc. (NASDAQ:PRVB): Profit margin
Mar 2022	580K	-21.96M	-3787.59%
Jun 2022	746K	-29.54M	-3959.92%
Sep 2022	756K	-28.18M	-3728.57%
Dec 2022	10.81M	-33.27M	-307.75%

Provention Bio, Inc. (NASDAQ:PRVB): Debt to assets
Mar 2022	122458000	28.25M	23.07%
Jun 2022	104353000	25.67M	24.6%
Sep 2022	193913000	49.14M	25.34%
Dec 2022	236856000	115.00M	48.56%

Provention Bio, Inc. (NASDAQ:PRVB): Cash Flow
Mar 2022	-15.03M	9.6M	2.15M
Jun 2022	-28.43M	-226K	11.63M
Sep 2022	-23.96M	-46.22M	114.69M
Dec 2022	-7.97M	-51.27M	905K

Provention Bio alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Provention Bio, Inc. (NASDAQ:PRVB): Employee count
Aug 2023	174
Sep 2023	174
Oct 2023	174
Nov 2023	174
Dec 2023	174
Jan 2024	174
Feb 2024	174
Mar 2024	174
Apr 2024	174
May 2024	174
Jun 2024	174
Jul 2024	174

Provention Bio
Hedge Funds Holdings Q1 2023

30.62% -40.98%

of PRVB is owned by hedge funds

108 -27

hedge funds hold PRVB stock

19.31M -25.85M

shares is hold by hedge funds

PRVB hedge funds holdings changes

Provention Bio
Insider Trading

Provention Bio, Inc. (NASDAQ:PRVB): Insider trades (number of shares)
Period	Buy	Sel
Dec 2022	0	199617
Jan 2023	0	3048180
Feb 2023	0	156320
Apr 2023	0	2190549

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	14 Apr 2023	SESSA CAPITAL (MASTER), L.P. 10 percent owner 10 percent owner	Common Stock	2,190,549	$24.32	$53,274,152
Option	13 Feb 2023	LEON FRANCISCO officer: Chief Sc..	Stock Option (right to buy)	25,985	$2.5	$64,963
Sale	13 Feb 2023	LEON FRANCISCO officer: Chief Sc..	Common Stock	25,985	$10.04	$260,941
Option	13 Feb 2023	LEON FRANCISCO officer: Chief Sc..	Common Stock	25,985	$2.5	$64,963
Option	13 Feb 2023	PALMER ASHLEIGH director, officer: Director and CEO director, officer: Director and..	Stock Option (right to buy)	25,835	$2.5	$64,588
Sale	13 Feb 2023	PALMER ASHLEIGH director, officer: Director and CEO director, officer: Director and..	Common Stock	25,835	$10.04	$259,461
Option	13 Feb 2023	PALMER ASHLEIGH director, officer: Director and CEO director, officer: Director and..	Common Stock	25,835	$2.5	$64,588
Option	10 Feb 2023	LEON FRANCISCO officer: Chief Sc..	Stock Option (right to buy)	50,000	$2.5	$125,000
Sale	10 Feb 2023	LEON FRANCISCO officer: Chief Sc..	Common Stock	50,000	$10.11	$505,600
Option	10 Feb 2023	LEON FRANCISCO officer: Chief Sc..	Common Stock	50,000	$2.5	$125,000

PRVB insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application METHODS AND COMPOSITIONS FOR TREATMENT OF LUPUS Filling date: 1 Nov 2021 Issue date: 26 May 2022	1 Nov 2021	26 May 2022
Application	Application Methods and Compositions for Preventing Type 1 Diabetes Filling date: 11 Jun 2021 Issue date: 10 Feb 2022	11 Jun 2021	10 Feb 2022
Application	Application Methods and Compositions for Reducing Immunogenicity By Non-Depletional B Cell Inhibitors Filling date: 7 Jan 2021 Issue date: 6 May 2021	7 Jan 2021	6 May 2021
Application	Application Methods and Compositions for Reducing Immunogenicity By Non-Depletional B Cell Inhibitors Filling date: 30 Jul 2020 Issue date: 4 Feb 2021	30 Jul 2020	4 Feb 2021
Application	Application Methods and Compositions for Preventing Type 1 Diabetes Filling date: 14 May 2020 Issue date: 24 Dec 2020	14 May 2020	24 Dec 2020

Provention Bio
Earnings Call Transcripts

Quarter	Transcript
Q3 2022 3 Nov 2022	Q3 2022 Earnings Call Transcript
Q2 2022 6 Aug 2022	Q2 2022 Earnings Call Transcript
Q1 2022 5 May 2022	Q1 2022 Earnings Call Transcript
Q4 2021 24 Feb 2022	Q4 2021 Earnings Call Transcript

PRVB earnings call transcripts

Provention Bio
Executives

Insider	Age	Compensation
Mr. Ashleigh W. Palmer B.Sc., M.B.A. (1963) Co-Founder, Pres, Chief Executive Officer & Director	62	$874,150
Dr. Eleanor L. Ramos (1956) Chief Medical Officer	69	$635,600
Dr. Francisco Leon M.D., Ph.D. (1972) Co-Founder & Chief Scientific Officer	53	$603,000
Mr. Jason Hoitt (1978) Chief Commercial Officer	47	$591,330
Mr. Andrew T. Drechsler (1972) Special Advisor	53	$589,400

Provention Bio
Latest News

Wednesday, 26 April 2023
02:00	Press Release: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Provention Bio, Inc.	globenewswire.com
Monday, 10 April 2023
22:58	The 5 Best- and Worst-Performing Mid-Cap Stocks in March 2023	24/7 Wall Street
Thursday, 16 March 2023
16:56	Why Provention Bio Stock Skyrocketed 256% This Week	The Motley Fool
Tuesday, 14 March 2023
13:44	Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi	Zacks Investment Research
Monday, 13 March 2023
20:22	This biopharma stock jumped over 250% on Monday: what happened?	Invezz
19:15	Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners	The Motley Fool
11:17	Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio	Market Watch
10:15	Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash deal	Proactive Investors
08:13	Why Is Provention Bio (PRVB) Stock Up 263% Today?	InvestorPlace
07:00	Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call	PRNewsWire
06:43	Sanofi To Buy Provention Bio In $2.9 Billion Deal (SNY) (PRVB)	Pulse2
02:49	Sanofi to buy Provention Bio in deal worth $2.9 billion	Market Watch
Thursday, 23 February 2023
08:30	Provention Bio to Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023	PRNewsWire
Wednesday, 22 February 2023
09:13	Provention Bio: Good Prospects In Type 1 Diabetes, But Patent Protection Is A Worry	Seeking Alpha
08:30	2 Beaten-Down Stocks That Might Be too Cheap to Ignore	The Motley Fool
Monday, 13 February 2023
08:17	Provention Bio, Inc. (PRVB) Surges 11.5%: Is This an Indication of Further Gains?	Zacks Investment Research
Wednesday, 8 February 2023
10:32	Here's Why 'Trend' Investors Would Love Betting on Provention Bio, Inc. (PRVB)	Zacks Investment Research
Tuesday, 7 February 2023
06:28	Provention Bio: Ability To Expand T1D Market Presence With Second Half 2023 Data	Seeking Alpha
Monday, 2 January 2023
12:44	Provention Bio: Tzield Finally Approved, But Neutral On Its Commercial Launch	Seeking Alpha
Monday, 5 December 2022
11:21	Why Shares of Provention Bio Went Up 30.3% in November	The Motley Fool
Sunday, 4 December 2022
10:15	Is This Biotech Stock a Buy Following a Landmark Approval?	The Motley Fool
Friday, 18 November 2022
11:36	Provention Bio gets FDA approval for treatment that can delay onset of Type 1 diabetes	Market Watch
Thursday, 3 November 2022
21:19	Provention Bio, Inc. (PRVB) Q3 2022 Earnings Call Transcript	Seeking Alpha
15:34	Why Is Provention Biosciences (PRVB) Stock Up 25% Today?	InvestorPlace
09:47	Provention Bio, Inc. (PRVB) Reports Q3 Loss, Misses Revenue Estimates	Zacks Investment Research
Friday, 7 October 2022
13:33	Provention (PRVB) Up on Deal With Sanofi for Diabetes Drug	Zacks Investment Research
09:47	Strength Seen in Provention Bio, Inc. (PRVB): Can Its 25.7% Jump Turn into More Strength?	Zacks Investment Research
Thursday, 6 October 2022
09:19	2 Stocks Jumping in Thursday's Premarket Trading	The Motley Fool
Thursday, 22 September 2022
10:53	1 Green Flag and 1 Red Flag for Provention Bio	The Motley Fool
Tuesday, 6 September 2022
16:01	Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference	PRNewsWire

Ideas & Opinions

Seeking Alpha 22 Feb 2023

Provention Bio: Good Prospects In Type 1 Diabetes, But Patent Protection Is A Worry
Seeking Alpha 7 Feb 2023

Provention Bio: Ability To Expand T1D Market Presence With Second Half 2023 Data
Seeking Alpha 2 Jan 2023

Provention Bio: Tzield Finally Approved, But Neutral On Its Commercial Launch
Seeking Alpha 25 Nov 2022

Provention Bio: Assessing The Investment Case After Teplizumab Approval
Seeking Alpha 12 Aug 2022

Provention Bio: More Risk, More Dilution Ahead - Downgrading To A Sell Rating
Seeking Alpha 4 Feb 2022

Provention Bio: Upgrading To A Strong-Buy, Potential Cure For Type 1 Diabetes
Seeking Alpha 30 Jul 2021

Provention Bio: Blood (Glucose) In The Streets
Seeking Alpha 27 Jul 2021

Altimmune: NASH And Obesity At The End Of The COVID Tunnel
Seeking Alpha 23 Jun 2021

Provention Bio: PDUFA Ahead, But Uncertainties Abound
Seeking Alpha 9 Apr 2021

Provention Bio: Oversold Territory, An Attractive Buying Opportunity

Frequently Asked Questions (FAQ)

When is Provention Bio's next earnings date?

Unfortunately, Provention Bio's (PRVB) next earnings date is currently unknown.
Does Provention Bio pay dividends?

No, Provention Bio does not pay dividends.
How much money does Provention Bio make?

Provention Bio has a market capitalization of 2.37B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 824.37% to 12.9M US dollars.
What is Provention Bio's stock symbol?

Provention Bio, Inc. is traded on the NASDAQ under the ticker symbol "PRVB".
What is Provention Bio's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Provention Bio?

Shares of Provention Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Provention Bio's key executives?
Provention Bio's management team includes the following people:
- Mr. Ashleigh W. Palmer B.Sc., M.B.A. Co-Founder, Pres, Chief Executive Officer & Director(age: 62, pay: $874,150)
- Dr. Eleanor L. Ramos Chief Medical Officer(age: 69, pay: $635,600)
- Dr. Francisco Leon M.D., Ph.D. Co-Founder & Chief Scientific Officer(age: 53, pay: $603,000)
- Mr. Jason Hoitt Chief Commercial Officer(age: 47, pay: $591,330)
- Mr. Andrew T. Drechsler Special Advisor(age: 53, pay: $589,400)
Is Provention Bio founder-led company?

Yes, Provention Bio is a company led by its founders Mr. Ashleigh W. Palmer B.Sc., M.B.A. and Dr. Francisco Leon M.D., Ph.D..
How many employees does Provention Bio have?

As Jul 2024, Provention Bio employs 174 workers.
When Provention Bio went public?

Provention Bio, Inc. is publicly traded company for more then 7 years since IPO on 24 Jul 2018.
What is Provention Bio's official website?

The official website for Provention Bio is proventionbio.com.
Where are Provention Bio's headquarters?

Provention Bio is headquartered at 55 Broad Street, Red Bank, NJ.
How can i contact Provention Bio?

Provention Bio's mailing address is 55 Broad Street, Red Bank, NJ and company can be reached via phone at +90 83360360.

Provention Bio, Inc.

proventionbio.com

Exchange:

NASDAQ

Full time employees:

174

Industry:

Biotechnology

Sector:

Healthcare

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

+90 83360360

55 Broad Street
Red Bank, NJ 07701

CIK: 0001695357
ISIN: US74374N1028
CUSIP: 74374N102